Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Terns Pharmaceuticals, Inc. TERN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
46/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$55.67
+5.7%

Terns Pharmaceuticals, Inc. (TERN) is a Biotechnology company in the Healthcare sector, currently trading at $52.68. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is TERN = $56 (+5.7% upside).

Valuation: TERN trades at a trailing Price-to-Earnings (P/E) of -51 (S&P 500 average ~25).

Net income is $96M (loss), growing at -18.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $919,000 against $1.0B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 62.41 (strong liquidity). Debt-to-assets is 0.1%. Total assets: $1.0B.

Analyst outlook: 10 / 16 analysts rate TERN as buy (63%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 61/100 (Pass), Income ?/100 (Fail).

$55.67
▲ 5.68% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Terns Pharmaceuticals, Inc., the average price target is $55.67, with a high forecast of $70.00, and a low forecast of $35.00.
Highest Price Target
$70.00
Average Price Target
$55.67
Lowest Price Target
$35.00

TERN SharesGrow Score Overview

55/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 60/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 61/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TERN

✓
VALUE Pass
60/100
TERN trades at a trailing Price-to-Earnings (P/E) of -51 (S&P 500 average ~25). Forward PEG -2.41 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $56, implying +6.3% from the current price $53. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
TERN: +0%/yr revenue is, -18.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet TERN: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 62.41 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
TERN: Gross margin is 0% (+0 pp trend), $5B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
61/100
Analyst outlook: 10 / 16 analysts rate TERN as buy (63%). Analyst consensus target is $56 (+6.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.865-53.19
Volume3.78M
Avg Volume (30D)5.39M
Market Cap$4.75B
Beta (1Y)-0.38
Share Statistics
EPS (TTM)-1.03
Shares Outstanding$93.17M
IPO Date2021-02-05
Employees59
CEOMelita Sun Jung
Financial Highlights & Ratios
EBITDA$-110.12M
Net Income$-96.21M
Operating Income$-110.12M
Total Cash$1.02B
Total Debt$919K
Net Debt$-523.83M
Total Assets$1.03B
Price / Earnings (P/E)-51.1
Analyst Forecast
1Y Price Target$56.00
Target High$70.00
Target Low$35.00
Upside+6.3%
Rating ConsensusBuy
Analysts Covering16
Buy 63% Hold 38% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS8808811074

Price Chart

Track all markets on TradingView
TERN
Terns Pharmaceuticals, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
1.87 52WK RANGE 53.19

People Also View

DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$16.92
+2.73%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 ELDN
ELDN
Eledon Pharmaceuticals, Inc.
$3.20
-0.62%
 ABOS
ABOS
Acumen Pharmaceuticals, Inc.
$2.68
+6.77%
 PDSB
PDSB
PDS Biotechnology Corporation
$1.06
-2.75%
 MREO
MREO
Mereo BioPharma Group plc
$0.33
+2.81%
 XFOR
XFOR
X4 Pharmaceuticals, Inc.
$4.20
+1.69%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message